# Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide

> **NCT00990652** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 10 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00990652
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-04
- **Final completion:** 2012-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990652, "Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00990652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*